Entries by immunocity

Microbiotica Receives Crohn’s & Colitis Foundation Funding to Develop Ulcerative Colitis Therapeutic

5 April 2022 in /by

Collaboration with US-based non-profit underlines potential of Company’s ulcerative colitis work Cambridge, UK, 05 April 2022 – Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, today announces it has received project funding from the Crohn’s & Colitis Foundation, as part of their IBD Ventures program, for the development of therapies to treat inflammatory bowel […]

Microbiotica raises £50 million ($67 million) to advance pipeline of microbiome-based therapeutics

7 March 2022 in /by

 Funds Phase 1b clinical trials in immuno-oncology and ulcerative colitis and expansion of microbiome-based product pipeline to other indications Series B funding round co-led by new investors Tencent and Flerie Invest, with additional participation from British Patient Capital and existing investors Cambridge Innovation Capital, IP Group and Seventure Company on the trajectory to become […]